Management to meet with investors and potential partners during Biotech Showcase 2026 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing novel neuroplastogenic small-molecule…
Read More
Once issued, this new U.S. Patent will expand the scope of Enveric's EVM401 patent portfolio of potential neuroplastogenic molecules for non-hallucinogenic treatment of neuropsychiatric conditions. CAMBRIDGE, Mass. - Enveric Biosciences…
Read More
In Q3, Enveric continued toward clinical readiness for lead candidate EB-003, targeting neuropsychiatric indications, announcing additional positive data in a preclinical model of PTSD, successful completion of dose range finding…
Read More
Common Stock Will Begin Trading on a Split-Adjusted Basis on October 28, 2025 CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic…
Read More
New patent marks Enveric's 23rd issued U.S. patent for novel neuroplastogen molecules, increasing Enveric's intellectual property footprint and supporting the potential for pipeline expansion CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ:…
Read More
EB-003, Enveric's lead product candidate, is protected by a different patent family that includes an issued U.S. patent and pending U.S. and international patents, all of which are separate and…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that its Board…
Read More
Key CMC achievements advance EB-003 on the path to first-in-human trials CAMBRIDGE, Mass. - Enveric Biosciences (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the closing…
Read More
CAMBRIDGE, Mass. - Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced the entry…
Read More
